Area of research
Pathology and Forensic Medicine · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Multiple Sclerosis Research Studies, Advanced MRI Techniques and Applications, Peripheral Neuropathies and Disorders, and Polyomavirus and related diseases.
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis
Enabling new insights from old scans by repurposing clinical MRI archives for multiple sclerosis research
Periventricular gradients in axonal and myelin microstructure are present in people with multiple sclerosis having low and high disability
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis
Proportionality-based association metrics in count compositional data
How patients with multiple sclerosis acquire disability
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis (P1-1.Virtual)
Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis
A multicenter, open label, single-arm, phase 3b study (CONSONANCE) to assess efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 1 interim analysis of cognition outcomes (P1-1.Virtual)
Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data
Secondary Progressive Multiple Sclerosis
Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement
The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes
Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
Factors associated with health care utilization in pediatric multiple sclerosis
Evaluating the efficacy and safety of 6-week extended interval dosing of natalizumab via a prospective, controlled, randomized, open-label, rater-blinded phase 3b study (P3.2-095)
Loss of intrathalamic tissue integrity in pediatric-onset multiple sclerosis measured with DTI. (P5.2-039)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Numerical Solution of Partial Differential Equations: Algorithms, Analysis, and Applications
Applications and development of finite element exterior calculus
Development and applications of the finite element exterior calculus
Finite element exterior calculus and applications
Numerical Solution of Partial Differential Equations and Applications
IMA New Directions Program: Visitors and Short Courses
The Causes and Consequences of Differential Press Coverage of Legislators
Numerical Solution of Partial Differential Equations and Applications
Numerical Solution of Partial Differential Equations and Applications
Numerical Solution of Differential Equations in Mechanics
Institute for Mathematics and its Applications
Numerical Methods in General Relativity
Doctoral Dissertation in Political Science: Explaining Patterns of Regulatory Enforcement
Numerical Solution of Differential Equations in Mechanics
Mathematical Sciences: Numerical Solution of Differential Equations in Mechanics
Congress, The Press, and Political Accountability
Mathematical Sciences: Numerical Solution of Differential Equations in Mechanics
Mathematical Sciences Computing Research Environments
Mathematical Sciences: Differential Equations of Mechanics and their Numerical Solution
Mathematical Sciences: Differential Equations of Mechanics and Their Numerical Solution
Mathematical Sciences: Boundary Element and Finite Element Methods for Partial Differential Equations
Mathematical Sciences Research Equipment